421 related articles for article (PubMed ID: 23159849)
1. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
2. Elevated estrogen receptor-α in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCA1/Rad51 interaction.
Jung YS; Chun HY; Yoon MH; Park BJ
Neoplasia; 2014 Dec; 16(12):1070-81. PubMed ID: 25499220
[TBL] [Abstract][Full Text] [Related]
3. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
5. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
Zhou L; Yang H
PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
[TBL] [Abstract][Full Text] [Related]
6. WSB1 promotes tumor metastasis by inducing pVHL degradation.
Kim JJ; Lee SB; Jang J; Yi SY; Kim SH; Han SA; Lee JM; Tong SY; Vincelette ND; Gao B; Yin P; Evans D; Choi DW; Qin B; Liu T; Zhang H; Deng M; Jen J; Zhang J; Wang L; Lou Z
Genes Dev; 2015 Nov; 29(21):2244-57. PubMed ID: 26545811
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
8. Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1alpha.
André H; Pereira TS
J Biol Chem; 2008 Oct; 283(43):29375-84. PubMed ID: 18694926
[TBL] [Abstract][Full Text] [Related]
9. USP9X destabilizes pVHL and promotes cell proliferation.
Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
[TBL] [Abstract][Full Text] [Related]
10. VBP1 represses cancer metastasis by enhancing HIF-1α degradation induced by pVHL.
Kim JA; Choi DK; Min JS; Kang I; Kim JC; Kim S; Ahn JK
FEBS J; 2018 Jan; 285(1):115-126. PubMed ID: 29121446
[TBL] [Abstract][Full Text] [Related]
11. The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.
Foxler DE; Bridge KS; James V; Webb TM; Mee M; Wong SC; Feng Y; Constantin-Teodosiu D; Petursdottir TE; Bjornsson J; Ingvarsson S; Ratcliffe PJ; Longmore GD; Sharp TV
Nat Cell Biol; 2012 Jan; 14(2):201-8. PubMed ID: 22286099
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
[TBL] [Abstract][Full Text] [Related]
13. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
14. Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.
Merlo A; Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Pitiot AS; Balbín M; Astudillo A; Valdés N; Scola B; Del Toro R; Méndez-Ferrer S; Piruat JI; Suarez C; Chiara MD
Oncotarget; 2017 Jan; 8(4):6700-6717. PubMed ID: 28036268
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
[TBL] [Abstract][Full Text] [Related]
16. Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.
Frost J; Rocha S; Ciulli A
J Biol Chem; 2021 Aug; 297(2):100910. PubMed ID: 34174286
[TBL] [Abstract][Full Text] [Related]
17. Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.
Okumura F; Uematsu K; Byrne SD; Hirano M; Joo-Okumura A; Nishikimi A; Shuin T; Fukui Y; Nakatsukasa K; Kamura T
Mol Cell Biol; 2016 Jun; 36(12):1803-17. PubMed ID: 27090638
[TBL] [Abstract][Full Text] [Related]
18. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
19. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
